TABLE 1.
Extent of anthrax exposure following a target B. anthracis spore challenge of 200 times the LD50 in New Zealand White rabbits in which treatment was initiated at 84 h postchallenge
| Group | Multiple of LD50 |
||
|---|---|---|---|
| Mean ± SD | Median | Range | |
| Spore-challenged rabbits (n = 180) | 187.5 ± 45.1 | 183 | 83.0–348.0 |
| Rabbits that died before treatmenta (n = 104) | 188.6 ± 43.5 | 183 | 86.0–305.0 |
| Rabbits that survived until treatment withb: | |||
| LVX + placebo (n = 37) | 173.8 ± 43.1 | 162 | 83.0–277.0 |
| LVX + raxibacumab (n = 39) | 197.4 ± 49.1 | 198 | 105.0–348.0 |
a
Rabbits that were challenged and died before treatment.
b
Rabbits that survived until the 84-h postchallenge treatment time. Rabbits were administered daily 50-mg/kg LVX doses intragastrically for 3 days. Immediately after the first LVX dose, rabbits were administered a single intravenous injection of placebo or 40 mg/kg raxibacumab. P was 0.0291 for the difference between the two treatment groups and was determined by a one-way ANOVA.